JP2019508017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508017A5 JP2019508017A5 JP2018531337A JP2018531337A JP2019508017A5 JP 2019508017 A5 JP2019508017 A5 JP 2019508017A5 JP 2018531337 A JP2018531337 A JP 2018531337A JP 2018531337 A JP2018531337 A JP 2018531337A JP 2019508017 A5 JP2019508017 A5 JP 2019508017A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- oncolytic virus
- defective
- antibody
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 244000309459 oncolytic virus Species 0.000 claims 41
- 239000013598 vector Substances 0.000 claims 20
- -1 CD31 Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 230000010076 replication Effects 0.000 claims 11
- 108700019146 Transgenes Proteins 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 8
- 230000002950 deficient Effects 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 5
- 108010012236 Chemokines Proteins 0.000 claims 5
- 108700012434 CCL3 Proteins 0.000 claims 4
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 102100025221 CD70 antigen Human genes 0.000 claims 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 102000004890 Interleukin-8 Human genes 0.000 claims 3
- 102000004473 OX40 Ligand Human genes 0.000 claims 3
- 108010042215 OX40 Ligand Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 102000002627 4-1BB Ligand Human genes 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 2
- 102100037354 Ectodysplasin-A Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 claims 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims 2
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 2
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims 2
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims 2
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 101150052608 SIVA1 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 108700012411 TNFSF10 Proteins 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000002101 lytic effect Effects 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 1
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 claims 1
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 claims 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 101710093458 ICOS ligand Proteins 0.000 claims 1
- 102000039996 IL-1 family Human genes 0.000 claims 1
- 108091069196 IL-1 family Proteins 0.000 claims 1
- 102000039989 IL-17 family Human genes 0.000 claims 1
- 108091069193 IL-17 family Proteins 0.000 claims 1
- 108091069192 IL-2 family Proteins 0.000 claims 1
- 102000039990 IL-2 family Human genes 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 1
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 claims 1
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 claims 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100028762 Neuropilin-1 Human genes 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 241000837158 Senecavirus A Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100026966 Thrombomodulin Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 108700014844 flt3 ligand Proteins 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000937 inactivator Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960003816 muromonab-cd3 Drugs 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 229950002610 otelixizumab Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522334.0A GB201522334D0 (en) | 2015-12-17 | 2015-12-17 | Method |
| GB1522334.0 | 2015-12-17 | ||
| GB1607463.5 | 2016-04-29 | ||
| GBGB1607463.5A GB201607463D0 (en) | 2016-04-29 | 2016-04-29 | Method |
| GB1617206.6 | 2016-10-10 | ||
| GBGB1617207.4A GB201617207D0 (en) | 2016-10-10 | 2016-10-10 | Method |
| GB1617207.4 | 2016-10-10 | ||
| GBGB1617206.6A GB201617206D0 (en) | 2016-10-10 | 2016-10-10 | Method |
| PCT/EP2016/081818 WO2017103291A1 (en) | 2015-12-17 | 2016-12-19 | Virus encoding an anti-tcr-complex antibody or fragment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508017A JP2019508017A (ja) | 2019-03-28 |
| JP2019508017A5 true JP2019508017A5 (enExample) | 2020-02-06 |
Family
ID=57794239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531337A Ceased JP2019508017A (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするウイルス |
| JP2018531336A Active JP7064437B2 (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531336A Active JP7064437B2 (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11155622B2 (enExample) |
| EP (2) | EP3389683B8 (enExample) |
| JP (2) | JP2019508017A (enExample) |
| KR (2) | KR20180108590A (enExample) |
| CN (2) | CN108697746A (enExample) |
| AU (2) | AU2016369485B2 (enExample) |
| BR (2) | BR112018012180A2 (enExample) |
| CA (1) | CA3006859A1 (enExample) |
| CL (1) | CL2018001611A1 (enExample) |
| CO (1) | CO2018005945A2 (enExample) |
| DK (1) | DK3389682T3 (enExample) |
| EA (2) | EA201891022A1 (enExample) |
| IL (2) | IL260027B (enExample) |
| MX (1) | MX2018007249A (enExample) |
| MY (1) | MY193281A (enExample) |
| PH (1) | PH12018501291A1 (enExample) |
| SG (2) | SG11201805136TA (enExample) |
| WO (2) | WO2017103290A1 (enExample) |
| ZA (1) | ZA201803523B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| BR122018004815A2 (pt) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | adenovírus oncolítico que codifica proteína b7 |
| MA43163A (fr) | 2015-11-02 | 2018-09-12 | Five Prime Therapeutics Inc | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| WO2022047417A1 (en) * | 2020-08-31 | 2022-03-03 | Exuma Biotech Corp. | Anti-idiotype compositions and methods of use thereof |
| EP3478321A4 (en) * | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| GB201713765D0 (en) * | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| JP2020517913A (ja) | 2017-04-28 | 2020-06-18 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドによる治療方法 |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| KR20200042904A (ko) * | 2017-07-26 | 2020-04-24 | 온코루스, 인크. | 종양용해성 바이러스 벡터 및 그의 용도 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| US12404312B2 (en) | 2018-03-05 | 2025-09-02 | Massachusetts Eye And Ear Infirmary | Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| EP3789489A4 (en) * | 2018-03-30 | 2022-01-05 | Tomoki Todo | ANTI-SWEEPER TYPE ONCOLYTIC VIRUS |
| JP2021529531A (ja) * | 2018-06-29 | 2021-11-04 | クリスタル バイオテック インコーポレイテッド | 抗体送達のための組成物及び方法 |
| WO2020050630A1 (ko) | 2018-09-07 | 2020-03-12 | 주식회사 케이티 | 비면허 대역에서 무선 통신을 수행하는 방법 및 장치 |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| WO2020143221A1 (zh) * | 2019-01-07 | 2020-07-16 | 四川安可康生物医药有限公司 | 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用 |
| US20200215133A1 (en) * | 2019-01-07 | 2020-07-09 | Sichuan Oncocare Biopharmaceutical, Inc. | Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| KR20220093103A (ko) * | 2019-09-13 | 2022-07-05 | 어드메어 테라퓨틱스 소사이어티 | 항종양용해 바이러스 항원 항체 및 이의 사용 방법 |
| WO2021073624A1 (zh) * | 2019-10-17 | 2021-04-22 | 北京门罗生物科技有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
| EP4114925B1 (en) * | 2020-03-04 | 2025-11-05 | Bioeclipse Therapeutics, Inc. | Methods of manufacturing activated immune cells |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN112063588A (zh) * | 2020-08-13 | 2020-12-11 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| KR20220105139A (ko) * | 2021-01-19 | 2022-07-26 | 광주과학기술원 | Igsf4의 막 관통 도메인을 발현하는 t 세포 및 이의 이용 |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| CN113544263B (zh) * | 2021-06-03 | 2022-12-06 | 上海允英生物医药科技有限公司 | 溶瘤病毒载体及其应用 |
| CN113355296A (zh) * | 2021-06-07 | 2021-09-07 | 中国人民解放军空军军医大学 | 一种表达人ccl19的重组溶瘤新城疫病毒及其应用 |
| CN116024175A (zh) * | 2021-10-27 | 2023-04-28 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| CN118696055A (zh) | 2021-12-23 | 2024-09-24 | 赫尔辛基大学 | 筛选用于在哺乳动物细胞中有效表达和分泌异源多肽的信号肽的方法 |
| CN114891126B (zh) * | 2022-06-23 | 2023-05-09 | 上海安库生医生物科技有限公司 | 一种靶向fshr和cd3分子的双结合蛋白及其应用 |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| DE69838510T2 (de) | 1997-02-20 | 2008-07-03 | Johns Hopkins University School Of Medicine | Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| CA2342396A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
| HK1045716A1 (zh) | 1999-04-09 | 2002-12-06 | 阿文蒂斯药物股份有限公司 | 用於保存感染性重組腺病毒的組合物 |
| EP1816204B1 (en) | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| EP1181382B1 (en) | 1999-06-01 | 2005-03-23 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP1348030B1 (en) | 2001-01-04 | 2009-11-25 | Wadell, Göran | Viral vector for gene therapy |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| AU2003206815A2 (en) | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| CA2527369A1 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| WO2005118825A2 (en) | 2004-05-26 | 2005-12-15 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| WO2006039045A2 (en) | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| JP2008050051A (ja) | 2006-08-28 | 2008-03-06 | Bokuson Uesuto:Kk | ディスペンスヘッド |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| MX339014B (es) | 2008-05-27 | 2016-05-09 | Oncolytics Biotech Inc | Modulacion de presion intersticial y suministro y distribucion viral oncolitica. |
| BRPI0919840B1 (pt) | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| EP2606127B1 (en) | 2010-08-16 | 2019-03-20 | Salk Institute For Biological Studies | Adenoviral assembly method |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| PT2748201T (pt) | 2011-08-23 | 2018-02-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas que ativam as células t |
| JP2015507604A (ja) | 2011-11-14 | 2015-03-12 | リジェネレイティブ サイエンシーズ， エルエルシー | 懸濁粒子送達システムおよび方法 |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) * | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| TR201802728T4 (tr) | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| WO2016030489A2 (en) | 2014-08-27 | 2016-03-03 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| CN107406859A (zh) | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途 |
| BR122018004815A2 (pt) | 2015-04-30 | 2019-09-10 | Psioxus Therapeutics Ltd | adenovírus oncolítico que codifica proteína b7 |
| EA201891022A1 (ru) | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| JP2019508044A (ja) | 2016-03-18 | 2019-03-28 | ナントセル，インコーポレイテッド | 樹状細胞感染のための多モードベクター |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-12-19 EA EA201891022A patent/EA201891022A1/ru unknown
- 2016-12-19 CN CN201680076032.7A patent/CN108697746A/zh active Pending
- 2016-12-19 IL IL260027A patent/IL260027B/en unknown
- 2016-12-19 AU AU2016369485A patent/AU2016369485B2/en active Active
- 2016-12-19 WO PCT/EP2016/081817 patent/WO2017103290A1/en not_active Ceased
- 2016-12-19 EP EP16825728.5A patent/EP3389683B8/en active Active
- 2016-12-19 AU AU2016372576A patent/AU2016372576A1/en not_active Abandoned
- 2016-12-19 WO PCT/EP2016/081818 patent/WO2017103291A1/en not_active Ceased
- 2016-12-19 BR BR112018012180A patent/BR112018012180A2/pt not_active IP Right Cessation
- 2016-12-19 JP JP2018531337A patent/JP2019508017A/ja not_active Ceased
- 2016-12-19 KR KR1020187020443A patent/KR20180108590A/ko not_active Withdrawn
- 2016-12-19 CA CA3006859A patent/CA3006859A1/en active Pending
- 2016-12-19 MY MYPI2018702073A patent/MY193281A/en unknown
- 2016-12-19 US US16/062,024 patent/US11155622B2/en active Active
- 2016-12-19 EA EA201891021A patent/EA201891021A1/ru unknown
- 2016-12-19 SG SG11201805136TA patent/SG11201805136TA/en unknown
- 2016-12-19 US US16/062,036 patent/US11970536B2/en active Active
- 2016-12-19 MX MX2018007249A patent/MX2018007249A/es unknown
- 2016-12-19 SG SG11201805137XA patent/SG11201805137XA/en unknown
- 2016-12-19 DK DK16825727.7T patent/DK3389682T3/da active
- 2016-12-19 KR KR1020187020442A patent/KR102857666B1/ko active Active
- 2016-12-19 EP EP16825727.7A patent/EP3389682B1/en active Active
- 2016-12-19 JP JP2018531336A patent/JP7064437B2/ja active Active
- 2016-12-19 BR BR112018012179A patent/BR112018012179A2/pt not_active IP Right Cessation
- 2016-12-19 CN CN201680074772.7A patent/CN108697745A/zh active Pending
-
2018
- 2018-05-28 ZA ZA2018/03523A patent/ZA201803523B/en unknown
- 2018-06-12 CO CONC2018/0005945A patent/CO2018005945A2/es unknown
- 2018-06-14 CL CL2018001611A patent/CL2018001611A1/es unknown
- 2018-06-14 IL IL260033A patent/IL260033A/en unknown
- 2018-06-18 PH PH12018501291A patent/PH12018501291A1/en unknown
-
2023
- 2023-11-27 US US18/520,030 patent/US20240247061A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508017A5 (enExample) | ||
| JP2019502379A5 (enExample) | ||
| HRP20200439T1 (hr) | Onkolitički adenovirus koji kodira protein b7 | |
| Eriksson et al. | Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment | |
| CN108431210B (zh) | 培养细胞的方法及用于该方法的试剂盒和设备 | |
| JP2018514199A5 (enExample) | ||
| Bonilla et al. | The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses | |
| O’Sullivan et al. | Interleukin-17D mediates tumor rejection through recruitment of natural killer cells | |
| Apostolidis et al. | The dysregulation of cytokine networks in systemic lupus erythematosus | |
| Fann et al. | Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T‐cell aging | |
| Nanki et al. | Cytokine, activation marker, and chemokine receptor expression by individual CD4+ memory T cells in rheumatoid arthritis synovium | |
| CN115003700B (zh) | 促实体瘤浸润的增强型cart细胞及其制备方法和细胞药物 | |
| Scheller et al. | Immunoreceptor engineering and synthetic cytokine signaling for therapeutics | |
| Koch et al. | Role of interferon-λ in allergic asthma | |
| Yamada et al. | Features of the cytokines secreted by adult T cell leukemia (ATL) cells | |
| CN111032850A (zh) | 寡聚粒子试剂及其使用方法 | |
| WO2015155370A4 (en) | Group b adenovirus modified in the e4orf4 region | |
| Pletnev et al. | Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20 | |
| JP2019500012A5 (enExample) | ||
| JP2017525364A5 (enExample) | ||
| AU2018277294A1 (en) | Oncolytic virus and method | |
| US12280092B2 (en) | Reprogrammed T cell-like NK cells | |
| Sebastian et al. | Signal transduction around thymic stromal lymphopoietin (TSLP) in atopic asthma | |
| CN113811602A (zh) | 一种可助推免疫细胞在体内扩增的佐剂 | |
| JP2019524111A5 (enExample) |